



Roberta Diaz Brinton, Ph.D.

Director, Center for Innovation in Brain Science, University of Arizona Health Sciences

Dr. Brinton leads the Center for Innovation in Brain Science at the University of Arizona, which is devoted to developing therapeutics for age-associated neurodegenerative disease including Alzheimer's disease (AD), Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis.

The Center is a hybrid translational ecosystem that harnesses the power of university-based research with the culture of biotech that spans discovery, translational, and clinical science.

She has authored more than 250 scientific publications, holds multiple patents, and founded two biotech start-ups, most recently, NeuTherapeutics.

She is an internationally recognized expert on AD whose discoveries have led to innovative therapeutics to prevent, delay, and treat the disease.

Dr. Brinton has conducted two National Institute on Aging (NIA)-funded Phase IIA clinical trials and is currently conducting three NIA Phase IIB clinical trials including the REGEN-BRAIN[®] trial of allopregnanolone to regenerate the AD brain and the PhytoSERM clinical trials to determine safety and efficacy to promote brain glucose metabolism and cognition and to alleviate menopausal symptoms.

Dr. Brinton service includes serving on the NIH Director's Advisory Committee, NIA Scientific Advisory Board, and Alzheimer's Drug Discovery Foundation Board of Governors.

Her honors include Scientist of the Year from the Alzheimer's Drug Discovery Foundation, Goodes Prize for Excellence in Alzheimer's Drug Discovery, Arizona Bioscience Researcher of the Year, and U.S. Presidential Citizens Medal, the highest civilian honor, for STEM education to advance underrepresented discoverers.

